Aleglitazar

A dual PPAR agonist drug candidate

Aleglitazar
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Aleglitazar is a pharmaceutical compound that was developed as a dual peroxisome proliferator-activated receptor (PPAR) agonist. It was primarily investigated for its potential use in the treatment of type 2 diabetes mellitus and associated cardiovascular disease.

Mechanism of Action

Aleglitazar functions as a dual agonist of the PPAR_ and PPAR_ receptors. These receptors are nuclear hormone receptors that regulate the expression of genes involved in glucose and lipid metabolism. By activating both PPAR_ and PPAR_, aleglitazar was intended to improve insulin sensitivity, reduce blood glucose levels, and favorably modify lipid profiles.

PPAR_ Agonism

PPAR_ is primarily expressed in the liver, heart, kidney, and muscle tissues. Activation of PPAR_ leads to increased fatty acid oxidation, reduced triglyceride levels, and improved high-density lipoprotein (HDL) cholesterol levels. This action is beneficial in reducing atherosclerosis and cardiovascular risk.

PPAR_ Agonism

PPAR_ is predominantly found in adipose tissue, the colon, and the immune system. Activation of PPAR_ enhances insulin sensitivity, promotes adipocyte differentiation, and modulates inflammatory responses. This can lead to improved glycemic control in patients with type 2 diabetes.

Clinical Development

Aleglitazar was developed by F. Hoffmann-La Roche and underwent several clinical trials to assess its efficacy and safety in patients with type 2 diabetes and cardiovascular disease. Despite initial promising results, further studies revealed concerns regarding safety and adverse effects.

Adverse Effects

During clinical trials, aleglitazar was associated with several adverse effects, including edema, heart failure, and renal impairment. These safety concerns ultimately led to the discontinuation of its development.

Discontinuation

In 2013, the development of aleglitazar was halted after the results of the ALECARDIO trial indicated that the risks outweighed the potential benefits. The trial showed no significant reduction in cardiovascular events and highlighted the increased risk of adverse effects.

Related Pages

• Type 2 diabetes mellitus
• Cardiovascular disease
• Peroxisome proliferator-activated receptor
• Insulin resistance

Gallery

• 
  Chemical structure of Aleglitazar